Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 17, 2013 - Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinival Trials in Patients with HER2 Mutations Read
- Dec. 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Read
- Nov. 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read
- Oct. 4, 2013 - Puma Biotechnology Initiates Phase II trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read
- Sept. 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read
- Aug. 6, 2013 - Puma Biotechnology Reports Second Quarter 2013 Financial Results Read
- June 24, 2013 - Puma Biotechnology to Join Russell 3000 Index Read
- June 7, 2013 - Puma Biotechnology Initiates Phase III trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
- June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read
- May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read
- May 17, 2013 - Puma Biotechnology Comment on trading Activity Read
- May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
- May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read
- May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read
- April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read
- Feb. 26, 2013 - Puma Biotechnology to Present at Cowen Health Care Conference Read
- Feb. 20, 2013 - Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
- Feb. 6, 2013 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read